Sight Sciences, Inc. (SGHT)
8.80
+0.55
(+6.67%)
USD |
NASDAQ |
Oct 15, 16:00
8.80
0.00 (0.00%)
After-Hours: 20:00
Sight Sciences Research and Development Expense (Quarterly) : 2.512M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.512M |
| March 31, 2026 | 2.546M |
| December 31, 2025 | 2.437M |
| September 30, 2025 | 3.352M |
| June 30, 2025 | 4.387M |
| March 31, 2025 | 4.43M |
| December 31, 2024 | 4.293M |
| September 30, 2024 | 4.746M |
| June 30, 2024 | 4.316M |
| March 31, 2024 | 4.636M |
| December 31, 2023 | 3.427M |
| September 30, 2023 | 4.239M |
| June 30, 2023 | 5.221M |
| Date | Value |
|---|---|
| March 31, 2023 | 4.669M |
| December 31, 2022 | 5.233M |
| September 30, 2022 | 6.053M |
| June 30, 2022 | 5.926M |
| March 31, 2022 | 5.646M |
| December 31, 2021 | 4.369M |
| September 30, 2021 | 4.279M |
| June 30, 2021 | 3.546M |
| March 31, 2021 | 3.44M |
| December 31, 2020 | 2.873M |
| September 30, 2020 | 2.158M |
| June 30, 2020 | 1.443M |
| March 31, 2020 | 2.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Integra LifeSciences Holdings Corp. | 21.74M |
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 7.979M |
| Alphatec Holdings, Inc. | 18.17M |
| AtriCure, Inc. | 25.67M |